FebriDx
FebriDx® and COVID-19 Triaging
The COVID-19 pandemic is placing a significant additional burden on all healthcare settings. Rapid identification of COVID-19 patients is critical to enable immediate isolation to prevent the spread of infection.

Molecular tests are available for SARS-CoV-2 but have been shown to have sub-optimal sensitivity and a turnaround time of ≥ 48 hours, causing delays in diagnosis which hampers patient isolation.1-2

During viral pandemics it is also imperative to ensure that patients with bacterial infections are not missed.3

FebriDx® is a highly sensitive and specific point-of-care (POC) test for both viral and bacterial infections. FebriDx® rapid viral vs. bacterial POC test can triage patients in just 10 minutes.4-5
Rapidly diagnose viral patients
Facilitate immediate patient isolation
Ensure patients with bacterial infections are not missed
Rule out non-clinically significant infection
COVID-19 FebriDx

Assess Your Patients Before They Enter the Emergency Department

COVID-19 FebriDx Process Flow

Two UK studies prospectively evaluated the real-world diagnostic accuracy of FebriDx® for the identification of COVID-19 in hospitalised adults.6-7

FebriDx® was highly accurate in identifying COVID-19 infections and detected cases that were missed by SARS-CoV-2 RT-PCR.6-7

FebriDx® viral negative patients can be rapidly cohorted in non-COVID-19 areas allowing viral positive patients to be immediately isolated whilst awaiting confirmatory PCR testing.6

“FebriDx® could be rapidly deployed as a front door triage tool in hospitals and urgent care centers to overcome current issues of delayed diagnosis from PCR testing.”7

Utility of FebriDx in early identification of possible COVID-19 Infection
Diagnostic accuracy of the FebriDx host response point-of-care test in patients hospitalised with suspected COVID-19

1. Fang Y, Zhang H, Xie J, et al. Sensitivity of chest CT for COVID-19: comparison to RT-PCR. Radiol. 2020:200432.
2. Zhao J, Yuan Q, Wang H, Liu W, Liao X, Su Y, et al. Antibody responses to SARS-CoV-2 in patients of novel coronavirus disease 2019. Clin Infect Dis. 2020;Eub ahead of print.
3. Cunha BA, Klein NC, Strollo S, Syed U, Mickail N, Laguerre M. Legionnaires’ disease mimicking swine influenza (H1N1) pneumonia during the ‘‘herald wave’’ of the pandemic. Heart Lung. 2010;39:242-48
4. Shapiro NI, Self WH, Rosen J, Sharp SC, Filbin MR, Hou PC, et al. A prospective, multi-centre US clinical trial to determine accuracy of FebriDx point-of-care testing for acute upper respiratory infections with and without a confirmed fever. Ann Med. 2018;50(5):420-29. https://doi.org/10.1080/07853890.2018.1474002
5. Self WH, Rosen J, Sharp SC, Filbin MR, Hou PC, Parekh AD, et al. Diagnostic accuracy of FebriDx: A rapid test to detect immune responses to viral and bacterial upper respiratory infections. J Clin Med. 2017;6(10):94.
6. Karim N, Ashraf MZ, Naseem M, et al. Utility of FebriDx in early identification of possible COVID-19 infection. Res Square. 2020;Epub ahead of print. https://www.researchsquare.com/article/rs-25802/v1
7. Clark TW, Brendish NJ, Poole S, et al. Diagnostic accuracy of the FebriDx host response point-of-care test in patients hospitalised with suspected COVID-19. J Infect. 2020;Epub ahead of print. doi: 10.1016/j.jinf.2020.06.051